<div class="container">

<table style="width: 100%;"><tr>
<td>aip</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>
Functions to calculate the appropriate dose level singletons
</h2>

<h3>Description</h3>

<p>Pool of functions to calculate dose level singletons values:
aip, ail2 and ait2 calculate sgl in order that E[psy] = prior,
ail1 and ait1 calculate sgl in order that psy(sgl,1) = prior.
</p>


<h3>Usage</h3>

<pre><code class="language-R">aip(p_prior, sd = 1.34)
ait1(p_prior, a=1)
ail1(p_prior, a=1)
ait2(p_prior)
ail2(p_prior)
</code></pre>


<h3>Arguments</h3>

<table>
<tr style="vertical-align: top;">
<td><code>p_prior</code></td>
<td>
<p>Prior toxicity probability.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>sd</code></td>
<td>
<p>Standard deviation in case of normal distribution for the parameter.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>a</code></td>
<td>
<p>Rate in case of exponential distribution for the parameter.
</p>
</td>
</tr>
</table>
<h3>Value</h3>

<p>Numeric length(p-prior)-vector.
</p>


<h3>Author(s)</h3>

<p>Benjamin Esterni, Baboukar Mane. Unite de Biostatistique et de Methodologie, Institut Paoli-Calmettes, Marseille, France.
</p>


<h3>References</h3>

<p>O'Quigley J., Pepe M., Fisher L. (1990). Continual Reassessment Method: a practical design for Phase I clinical trials in cancer. Biometrics 46, 33-48. &lt;https://doi.org/10.2307/2531628&gt;
</p>
<p>O'Quigley J., Shen LZ. (1996). Continual Reassessment Method: a likelihood approach. Biometrics 52, 673-684. &lt;https://doi.org/10.2307/2532905&gt;
</p>
<p>Paoletti X., Kramar A. (2009). A comparison of model choices for the Continual Reassessment Method in phase I cancer trials. Statistics in Medecine 28, 3012-3028. &lt;https://doi.org/10.1002/sim.3682&gt;
</p>
<p>Chamorey Emmanuel. (2009). Methodologie des essais de phase precoce en cancerologie: evolution des schemas et apport de la pharmacologie. These.
</p>
<p>Garret-Mayer Elizabeth. (2006). The Continual Reassessment Method for dose-finding studies: a tutorial. Clinical Trials: 57-71. &lt;https://doi.org/10.1191/1740774506cn134oa&gt;
</p>


</div>